Robert C. Colgrove, Jr., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endocarditis, Bacterial | 2 | 2023 | 444 | 1.320 |
Why?
|
| Endocarditis | 2 | 2023 | 351 | 1.310 |
Why?
|
| Klebsiella oxytoca | 1 | 2024 | 7 | 0.960 |
Why?
|
| Klebsiella Infections | 1 | 2024 | 147 | 0.840 |
Why?
|
| Enterobacteriaceae | 1 | 2024 | 172 | 0.840 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2024 | 192 | 0.810 |
Why?
|
| Herpesvirus 1, Human | 6 | 2016 | 753 | 0.670 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2021 | 124 | 0.660 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2023 | 529 | 0.650 |
Why?
|
| Herpesvirus 2, Human | 3 | 2015 | 190 | 0.640 |
Why?
|
| Epidemics | 1 | 2023 | 512 | 0.600 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 1943 | 0.600 |
Why?
|
| Genome, Viral | 3 | 2015 | 657 | 0.580 |
Why?
|
| Herpes Genitalis | 1 | 2013 | 142 | 0.420 |
Why?
|
| DNA, Viral | 3 | 2015 | 2195 | 0.350 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2006 | 1349 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 7379 | 0.260 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2005 | 93 | 0.240 |
Why?
|
| Reverse Transcriptase Inhibitors | 5 | 2007 | 618 | 0.240 |
Why?
|
| Zidovudine | 4 | 2004 | 624 | 0.240 |
Why?
|
| Gene Products, gag | 1 | 2005 | 312 | 0.230 |
Why?
|
| Utah | 1 | 2023 | 131 | 0.220 |
Why?
|
| Fungi | 1 | 2023 | 338 | 0.180 |
Why?
|
| Viral Proteins | 4 | 2015 | 1803 | 0.170 |
Why?
|
| Base Sequence | 5 | 2015 | 12442 | 0.160 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2000 | 212 | 0.160 |
Why?
|
| Anti-HIV Agents | 5 | 2007 | 4490 | 0.150 |
Why?
|
| Molecular Sequence Data | 6 | 2015 | 17611 | 0.150 |
Why?
|
| Vero Cells | 3 | 2015 | 484 | 0.150 |
Why?
|
| HIV-1 | 7 | 2007 | 6848 | 0.150 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 254 | 0.150 |
Why?
|
| HIV Infections | 9 | 2007 | 17126 | 0.150 |
Why?
|
| Viruses | 1 | 2020 | 376 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2024 | 1053 | 0.140 |
Why?
|
| Amino Acid Sequence | 5 | 2016 | 13439 | 0.140 |
Why?
|
| Viral Structural Proteins | 1 | 2016 | 95 | 0.130 |
Why?
|
| Herpes Simplex | 3 | 2011 | 477 | 0.130 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2016 | 45 | 0.130 |
Why?
|
| West Nile virus | 1 | 2016 | 76 | 0.130 |
Why?
|
| Cell Fusion | 2 | 2006 | 292 | 0.130 |
Why?
|
| Virus Replication | 4 | 2011 | 2431 | 0.120 |
Why?
|
| Serial Passage | 1 | 2013 | 23 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2022 | 879 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 1001 | 0.110 |
Why?
|
| Viral Envelope Proteins | 2 | 2006 | 638 | 0.100 |
Why?
|
| Drug Resistance, Viral | 3 | 2007 | 857 | 0.100 |
Why?
|
| HIV | 1 | 1999 | 1579 | 0.100 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2011 | 438 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2024 | 3730 | 0.090 |
Why?
|
| Genes, Immediate-Early | 1 | 2011 | 101 | 0.090 |
Why?
|
| Open Reading Frames | 1 | 2013 | 813 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2007 | 2123 | 0.090 |
Why?
|
| Gram-Positive Bacteria | 1 | 2010 | 178 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2015 | 2607 | 0.080 |
Why?
|
| Hepatitis B virus | 2 | 1989 | 517 | 0.080 |
Why?
|
| Humans | 25 | 2024 | 759098 | 0.080 |
Why?
|
| Genes, Viral | 1 | 1989 | 650 | 0.080 |
Why?
|
| Membrane Fusion | 2 | 2006 | 266 | 0.080 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 342 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 9587 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 3 | 2000 | 858 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2015 | 2202 | 0.070 |
Why?
|
| RNA, Viral | 7 | 2007 | 2837 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2016 | 3376 | 0.070 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2006 | 53 | 0.070 |
Why?
|
| Adenosine Triphosphatases | 1 | 2011 | 834 | 0.070 |
Why?
|
| Palmitic Acid | 1 | 2006 | 149 | 0.070 |
Why?
|
| United States | 2 | 2024 | 72238 | 0.060 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 728 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2005 | 12106 | 0.060 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 3684 | 0.060 |
Why?
|
| Incidence | 1 | 2023 | 21344 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4715 | 0.060 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 206 | 0.060 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2005 | 148 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 458 | 0.050 |
Why?
|
| Heterochromatin | 1 | 2005 | 293 | 0.050 |
Why?
|
| Male | 7 | 2024 | 358602 | 0.050 |
Why?
|
| Mutation | 5 | 2007 | 29878 | 0.050 |
Why?
|
| Virus Latency | 1 | 2005 | 362 | 0.050 |
Why?
|
| Phylogeny | 2 | 2023 | 2765 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2004 | 130 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2023 | 41932 | 0.050 |
Why?
|
| Chromatin | 2 | 2011 | 2940 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2005 | 1521 | 0.050 |
Why?
|
| Female | 10 | 2024 | 390174 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2015 | 6531 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 58864 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 1972 | 0.040 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1999 | 224 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2005 | 5790 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5778 | 0.040 |
Why?
|
| Genotype | 3 | 2022 | 12940 | 0.040 |
Why?
|
| Infant, Newborn | 5 | 2006 | 26099 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2005 | 2912 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 1989 | 7593 | 0.030 |
Why?
|
| Gene Order | 1 | 2016 | 169 | 0.030 |
Why?
|
| Binding Sites | 1 | 2005 | 6054 | 0.030 |
Why?
|
| Cell Line | 4 | 2016 | 15638 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 611 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2023 | 80125 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 2198 | 0.030 |
Why?
|
| Animals | 8 | 2016 | 167531 | 0.030 |
Why?
|
| Capsid | 1 | 2016 | 434 | 0.030 |
Why?
|
| Mice | 3 | 2016 | 80993 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 661 | 0.030 |
Why?
|
| Pregnancy | 5 | 2007 | 29650 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 168615 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3091 | 0.030 |
Why?
|
| Immunization | 1 | 2016 | 1215 | 0.020 |
Why?
|
| Adult | 3 | 2024 | 219353 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 219628 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 1527 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2010 | 260 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2010 | 279 | 0.020 |
Why?
|
| Viral Load | 3 | 2004 | 3317 | 0.020 |
Why?
|
| Point Mutation | 2 | 2005 | 1594 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1999 | 6490 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2023 | 8001 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2004 | 2569 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2006 | 3682 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 1930 | 0.020 |
Why?
|
| Tritium | 1 | 2006 | 707 | 0.020 |
Why?
|
| Nuclear Lamina | 1 | 2005 | 47 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 6070 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2005 | 69 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 879 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2006 | 388 | 0.020 |
Why?
|
| Viral Fusion Proteins | 1 | 2005 | 99 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 3143 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 432 | 0.010 |
Why?
|
| New York City | 1 | 2007 | 724 | 0.010 |
Why?
|
| Didanosine | 1 | 2004 | 151 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2006 | 1695 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 1756 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2006 | 12765 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 861 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 464 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 11046 | 0.010 |
Why?
|
| Cysteine | 1 | 2006 | 892 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2005 | 1494 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2005 | 1737 | 0.010 |
Why?
|
| Transfection | 1 | 1988 | 5781 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2004 | 680 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 1967 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 2814 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 3800 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2474 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2852 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 2049 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4563 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 4914 | 0.010 |
Why?
|
| Phenotype | 2 | 2004 | 16524 | 0.010 |
Why?
|
| Histones | 1 | 2005 | 2582 | 0.010 |
Why?
|
| Infant | 2 | 2006 | 35940 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 4526 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 5793 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2005 | 3797 | 0.010 |
Why?
|
| Ducks | 1 | 1988 | 11 | 0.010 |
Why?
|
| DNA, Circular | 1 | 1988 | 97 | 0.000 |
Why?
|
| Blotting, Southern | 1 | 1988 | 780 | 0.000 |
Why?
|
| DNA Probes | 1 | 1988 | 551 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 1304 | 0.000 |
Why?
|
| Blotting, Northern | 1 | 1988 | 1545 | 0.000 |
Why?
|
| Virion | 1 | 1988 | 421 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2004 | 21992 | 0.000 |
Why?
|
| Time Factors | 1 | 2005 | 40083 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2006 | 41266 | 0.000 |
Why?
|
| Plasmids | 1 | 1988 | 2277 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1988 | 4170 | 0.000 |
Why?
|
| DNA Replication | 1 | 1988 | 1413 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1988 | 6132 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2004 | 54190 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1988 | 2295 | 0.000 |
Why?
|
| Child | 1 | 2004 | 79604 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1988 | 4313 | 0.000 |
Why?
|